Windgap Medical, Inc. Closes Over $39 Million Of Series B-1 Investment, More Than Twenty Percent Over Its Initial Goal
Windgap Medical, Inc. Closes Over $39 Million Of Series B-1 Investment, More Than Twenty Percent Over Its Initial Goal
01/20/22, 8:44 AM
Location
watertownMoney raised
$39 million
Round Type
series b
Windgap Medical, Inc., a leading specialty pharmaceutical and drug delivery platform company, announced today that it has successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital. This equity round of investment expanded beyond an initial target of approximately $32 million due to strong investor interest. This equity financing is also supported by existing investors, including Shepherd Kaplan Krochuk (SKK) and Molex Ventures (a Koch Industries company), along with new investors including Cobro Ventures, and others.
Company Info
Location
watertown, south dakota, united states
Additional Info
Windgap Medical, Inc. is an emerging, privately-held pharmaceutical company in the Greater Boston area focused on developing patient solutions with its patented wet/dry drug delivery platforms. Its first product is for the administration of epinephrine for anaphylaxis with additional products under development in a variety of markets. Find more information on www.windgapmedical.com and follow the company on LinkedIn.
For Media Inquiries: Windgap Medical, Inc. Chris Stepanian, +1 617-440-3311 Chief Executive Officer 327988@email4pr.com
SOURCE Windgap Medical, Inc.